Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|

Found 111 Matches

Cefuroxime_V12R1_FDA_20150709
Model Files Publication
Table 1 of main paper and further discussion in supplemental file. IV only. Key feature is the use of mechanistic kidney model to simulate the effect of severe renal impairment and probenecid inhibition.
Search Score: 1
FostamatinibMetR406_V19R1_Pfizer_20210804
Model Files Publication
An optimized Rosuvastatin (V19) model was used and DDIs predominantly driven by gut BCRP inhibition are reasonably recovered. Altogether, the following inhibitors were used: Capmatinib Fenebrutinib Fostamatinib Itraconazole Zepatier The workspace represents the DDI between Rosuvastatin and Fostamatinib metabolite R406. Link to the publication with further details: http://doi.org/10.1002/psp4.12672
Search Score: 1
Pyrimethamine
Model Files Publication

Brand Name(s) include: Daraprim

Disease: Malaria

Drug Class: Antimalarials

Date Updated: November 2021

Model at-a-glance

  Absorption Model
  • First-Order

  Volume of Distribution 
  • Full PBPK (Method 2) 

Note: Kp scalar used

  Route of Elimination
  • Non-specific hepatic metabolism (metabolizing enzymes not known)

  Perpetrator DDI
  • OCT1 and OCT2 inhibitor

  Validation

  • Three clinical studies were available for model verification.  100% of simulated Cmax and AUC were within 1.5-fold of observed and hence the model performance was deemed acceptable.

  Limitations
  • The current model does not describe enzyme specific metabolism of pyrimethamine as there are no data for specific routes of metabolism.​

The current model does not mechanistically describe the absorption of pyrimethamine as the ADAM model over-predicts the extent of absorption. Although pyrimethamine is described as well absorbed in some literature, further analysis of the IV and PO data did not support this. 

  Updates in V19
  • Updated in vitro­ data
    • fup: 0.085 -> 0.095

 

Search Score: 1
Eltrombopag_RES_V21R1_Simcyp_20230615
Model Files Publication

Prepared: June 2023 The RES-Eltrombopag_V21 model has been developed primarily as an inhibitor of hepatic OATP1B1 and OATP1B3, and intestinal BCRP using the New GI physiology in Simcyp V21 with altered GI tract population inputs that became default in V22. The file is verified as tablet in the fasted state as that formulation was used in the Rosuvastatin DDI (Allred et al., 2011). The PK for Eltrombopag was evaluated at 25mg, 50mg and 75mg SD; 50mg QD, 100mg QD, 150mg QD, and 200mg QD.  Note, the Rosuvastatin DDI with 75mg QD was used to fit the BCRP component in Rosuvastatin V21 file using the New GI physiology. The BCRP component of Rosuvastatin was then verified with other BCRP-Inhibitors available on the members area (as specified in the attached document) or within the Simcyp Simulator. Allred, A. J., C. J. Bowen, J. W. Park, B. Peng, D. D. Williams, M. B. Wire, and E. Lee. 2011. “Eltrombopag Increases Plasma Rosuvastatin Exposure in Healthy Volunteers.” Journal Article. Br J Clin Pharmacol 72 (2): 321–29.

Search Score: 1

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|